Evidence map›Paper›PMID 39186379›Full record

ReviewJournal of the American Society of Nephrology : JASN2024

Aquaporin-1 and Osmosis: From Physiology to Precision in Peritoneal Dialysis.

Olivier Devuyst

Abstract readReview
In one paragraph

Review in Journal of the American Society of Nephrology : JASN, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Olivier DevuystMechanisms of Inherited Kidney Disorders, Institute of Physiology, University of Zurich, Zürich, Switzerland; and Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium.ORCID 0000-0003-3744-4767

Funding

European Rare Kidney Disease Reference Network 739532FP7 People: Marie-Curie Actions 860977Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030_189044University of Zurich URPP ITINERARE
6 · The paper itself

Abstract

The discovery of the aquaporin family of water channels has provided a molecular counterpart to the movement of water across biological membranes. The distribution of aquaporins in specific cell types, their selectivity and very high capacity for water permeation, and the control of their expression and/or trafficking are key to sustain osmosis in multiple tissues. Here, we review the convergent evidence demonstrating that aquaporin-1 (AQP1) facilitates water transport across endothelial cells in the peritoneal membrane, a key process for peritoneal dialysis-the leading modality of home-based dialysis therapy for patients with kidney failure. Genetic and pharmacologic studies in mouse and cell models indicated that AQP1 plays a critical role in crystalloid osmosis, with clinically relevant effects on water transport and risk of death and technique failure for patients on dialysis. By contrast, AQP1 plays no role in colloid osmosis. These studies substantiate potential strategies to improve free water transport and ultrafiltration in patients treated by peritoneal dialysis.

Indexed as

Aquaporin 1OsmosisPeritoneal DialysisAnimalsBiological TransportHumansMicePeritoneumWaterAQP1 protein, humanAquaporin 1Water

Identifiers

PMID39186379
PMCPMC11543016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.